Vifor Pharma AG
SIX:VIFN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CH |
V
|
Vifor Pharma AG
SIX:VIFN
|
10.8B CHF |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
541.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
270B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
218.4B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
94.9B EUR |
Loading...
|
Market Distribution
| Min | -62 472.2% |
| 30th Percentile | 3.5% |
| Median | 10.3% |
| 70th Percentile | 16.5% |
| Max | 91.2% |
Other Profitability Ratios
Vifor Pharma AG
Glance View
Vifor Pharma AG, originally a small entity in the Swiss pharmaceutical landscape, has carved out a niche specializing in iron deficiency therapies and treatments. The company's journey began with an acute recognition of the global prevalence of iron deficiency and its profound impact on health. This focus allowed Vifor Pharma to fill a critical gap in the medical market, driving innovation within a specific therapeutic area that, until their entrance, was underserved. Beyond iron deficiency, they expanded into other selective therapeutic sectors such as nephrology, offering solutions for patients with chronic kidney disease. These strategic choices propelled Vifor to diversify its portfolio with specialized products that address significant unmet medical needs, fostered through both in-house R&D efforts and strategic partnerships with global biotech firms. The operational model of Vifor Pharma is intricately tied to its stronghold on niche pharmaceuticals, making money through a blend of proprietary product sales and strategic licensing or partnership agreements. Its flagship product, Ferinject, a novel intravenous iron replacement therapy, exemplifies Vifor’s capability to transform research into lucrative market solutions. Revenue is bolstered through partnerships with other pharmaceutical giants, which help distribute and co-market these solutions globally, thus expanding Vifor’s reach and market penetration. By focusing on specialized treatments and harnessing relationships that extend its distribution potential, Vifor Pharma has consistently honed its ability to balance innovation with strategic commercialization, underpinning its steady financial growth in the global pharmaceutical arena.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
Over the last 3 years, Vifor Pharma AG’s Operating Margin has increased from 14.4% to 20.1%. During this period, it reached a low of 14.4% on Dec 1, 2018 and a high of 20.3% on Jun 30, 2021.